key: cord-0869854-17rk9wqj
authors: Kladnik, Jerneja; Dolinar, Ana; Kljun, Jakob; Perea, David; Grau-Expósito, Judith; Genescà, Meritxell; Novinec, Marko; Buzon, Maria J.; Turel, Iztok
title: Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
date: 2022-03-04
journal: bioRxiv
DOI: 10.1101/2022.03.03.482819
sha: a3a8fce91a000b3a10219afc4d8e7098b31f39eb
doc_id: 869854
cord_uid: 17rk9wqj

As SARS-CoV-2 triggered a global health crisis, there is an urgent need to provide patients with safe, effective, accessible, and preferably oral therapeutics for COVID-19 that complement mRNA vaccines. Zinc compounds are widely known for their antiviral properties. Therefore, we have prepared a library of zinc complexes with pyrithione (1-hydroxy-2(1H)-pyridinethione) and its analogues, all of which showed promising in vitro inhibition of cathepsin L, an enzyme involved in SARS-CoV-2 entry, and PLPro, an enzyme involved in SARS-CoV-2 replication both in (sub)micromolar range. Zinc pyrithione 1a is a well-established, commercially available antimicrobial agent and was therefore selected for further evaluation of its SARS-CoV-2 entry and replication inhibition in an ex vivo system derived from primary human lung tissue. Our results suggest that zinc pyrithione complex 1a provides a multitarget approach to combat SARS-CoV-2 and should be considered for repurposing as a potential therapeutic against the insidious COVID-19 disease. Featured image In our study, we show that zinc pyrithione holds immense potential for the development of a possible out-patient treatment for SARS-CoV-2 due to its inhibition of viral entry and replication.

Research and development of safe and effective pharmacotherapy for a life-threatening COVID-19 disease must now focus on curative approaches after the rapid and successful development of mRNA vaccines. The development of specific SARS-CoV-2 inhibitors requires a thorough knowledge of viral structure, host cell entry, and the replication cycle. 1 SARS-CoV-2 is an enveloped single-stranded positive-sense RNA virus 2 that requires binding of the viral spike protein to the human zinc metalloproteinase receptor ACE2 as the first step in internalization process. 3 After binding, viral entry is possible through i) direct fusion with the cell surface involving the proteases furin and transmembrane serine protease-2 (TMPRSS2), followed by direct release of SARS-CoV-2 RNA and/or ii) receptor-mediated endocytosis, in which the lysosomal cysteine protease cathepsin L facilitates the release of 3 the genetic material after fusion of the viral and endosomal membranes. 4 Once RNA is released into the cytosol, translation and replication of the genome occur, including the potential targets papain-like protease (PL Pro ), chymotrypsin-like protease (3CL Pro , also abbreviated as M Pro ), and RNA-dependent RNA polymerase (RdRp). After the synthesis of the viral structural proteins and their transition through endoplasmatic-reticulum-to-Golgi intermediate compartment, the viral copies are released from host cells by exocytosis. 5 To our knowledge, the following intravenous/subcutaneous treatments are currently approved by EMA and FDA: remdesivir targeting RdRp, and antibodies targeting the spike protein, i.e., casirivimab/imdevimab, regdanvimab, sotrovimab and bamlanivimab/etesevimab, as well as tocilizumab as an interleukin-6 blocker. In addition, anakinra, a subcutaneously applied interleukin-1 receptor antagonist and orally administered PF-07321332 (SARS-CoV-2-M Pro inhibitor) along with ritonavir (which slows down the metabolism of PF-07321332) were also authorized for COVID-19 treatment. Currently, molnupiravir (a ribonucleoside analogue that inhibits SARS-CoV-2 replication) and baricitinib (an immunosuppressant) are awaiting the green light for their marketing authorization. 6, 7 However, due to constant viral mutations, it is necessary to continue research and development of new therapeutic options with other targets. To skip the rigorous and lengthy process from potential drug candidate to its clinical approval, many investigations have been conducted to repurpose already approved drugs for COVID-19 indication. 8 Zinc is the second most abundant d-block metal in the human body and plays several important roles in biological systems (e.g., structural, catalytic, regulatory, signalling). 9 Zinc received much attention during the pandemic because of its antiviral, anti-inflammatory, and antioxidant properties. 10 In addition, hypozincemia has also been suspected to cause dysgeusia and anosmia, common COVID-19 symptoms, because taste and smell functions are regulated by the zinc-containing enzyme carbonic anhydrase. 11, 12 Many studies suggest 4 that zinc deficiency increases susceptibility to infectious diseases, including COVID-19. [13] [14] [15] [16] There is some evidence that Zn 2+ can indirectly inhibit ACE2 receptors 10, 17, 18 and furin was also reported to be inhibited by zinc. 19 Low bioavailability of zinc may also negatively affect the activity of signalling molecules (interferon type 1, tumor necrosis factor, interleukin IL- 6) leading to cytokine storm and severe lung damage. 18 A computational study has confirmed possible inhibition of RdRp and M Pro by zinc ions. 20, 21 Additionally, the crystal structure of SARS-CoV-2 M Pro has confirmed the interactions of Zn 2+ in the active site. 22, 23 Although the structural studies clearly confirmed that a zinc ion inhibits SARS-CoV-2 M Pro by binding to the active site, it was also found that the experimentally determined affinity between the protein and the metal ion does not appear to be high enough for any real therapeutic applications of zinc supplementation, at least in its ionic form. 22 In 2010, te Velthius et al. showed that the combination of Zn 2+ ions and pyrithione a (1hydroxy-2(1H)-pyridinethione or 2-pyridinethiol N-oxide, Fig. 1 ) successfully inhibited SARS-CoV replication, possibly by Zn 2+ suppression of RdRp activity. Inhibition of SARS-CoV was less potent with pyrithione itself and even less effective with zinc acetate alone. 24 Zinc pyrithione 1a has also been shown to effectively inhibit M Pro and PL Pro of SARS-CoV [25] [26] [27] as well as M Pro of SARS-CoV-2. [28] [29] [30] There are several reports that zinc pyrithione damages iron-sulfur (Fe-S) clusters and consequently elicits antimicrobial activity. [31] [32] [33] Recently, Maio et al. suggested that Fe-S clusters act as cofactors of the SARS-CoV-2 RdRp enzyme and therefore represent another potential target to combat COVID-19. 34 Based on the described data from the literature, we decided to further investigate a system of zinc and pyrithione as a promising antiviral combination against SARS-CoV-2. Our group has previously conducted an extensive research on biological properties of 5 organoruthenium(II) pyrithionato complexes, [35] [36] [37] [38] however, zinc appears to be more suitable to combat COVID-19. In addition to antiviral properties, zinc pyrithione has been thoroughly investigated before for other antimicrobial properties and is now used in commercial antidandruff shampoos, 32 and as antifouling agent in paints. 39 In this study, a small library of zinc compounds containing the ligand pyrithione and its analogues (1a-h) was prepared and tested on two SARS-CoV-2 targets, cathepsin L and PL Pro . In addition, the ligands themselves (a-h) and the ruthenium complex with pyrithione 2a were included to better understand the role of the metal centre (Fig. 1) . Based on the excellent results of in vitro enzyme inhibition, further ex vivo assays were performed to investigate the inhibition of SARS-CoV-2 entry as well as its replication.

First, pyrithionato ligands were prepared in a two-step synthesis and then complexed with the zinc ion (Fig. 1) . We prepared pyrithiones b-e with methyl substituents at different positions of the pyrithione backbone together with two pyrithiones f-g with extended aromaticity. In one of our publications, we have already shown that organoruthenium(II) chlorido and pta (1,3,5-triaza-7-phosphaadamantane) complexes with methyl-substituted pyrithione at position 3 exhibited enhanced cytotoxicity in seven cancer cell lines tested, compared with the chlorido/pta complexes with unsubstituted pyrithione. 36 Therefore, we hypothesised that the methyl group as a donor substituent at position 3 would lead to better stability of the complexes. Based on that, we prepared another pyrithione ligand h with a donor group at position 3, i.e., a methoxy substituent -OCH3. According to the concept of hard and soft acids and bases (HSAB) concept, zinc has a borderline character. It tends to form complexes with both hard oxygen and soft sulphur donors. Pyrithiones have the ability to coordinate well to 6 various metal ions via their sulfur and oxygen donor atoms to form metal complexes, and particularly stable complexes are formed with zinc (apparent Kd = 5.0 • 10 -12 M 2 ). 40

Zinc complexes 1a-h were prepared by a modified published procedure. 41 First, the corresponding pyrithione ligand a-h was dissolved in methanol. Before the addition of zinc acetate, the pyrithione ligand had to be deprotonated, which was achieved with an aqueous solution of 1M NaOH. After addition of zinc acetate to this solution, a white precipitate was obtained immediately, which was then filtered off and dried overnight in an oven. All compounds prepared were physico-chemically characterized by NMR (Supplementary Figs. [2] [3] [4] [5] [6] [7] [8] [9] , high resolution mass spectrometry, elemental analysis (C, H, N), IR spectroscopy and new crystal structures were also obtained for compounds 1d and 1f (see below).

In the literature it is described that the zinc pyrithione complex 1a crystallizes as a dimer with trigonal bipyramidal geometry, where the zinc ion is coordinated by five donor atoms (Fig.   2 ). Two pyrithionato units bind to the central zinc ion via S-and O-atoms to form a 7 monomeric subunit, which is further linked by an additional Zn-O coordination bond from another monomeric subunit to form a dimer. However, in solution zinc pyrithione exists as a monomer. 42 The crystal structure of zinc complex 1b is comparable to that of the zinc pyrithione complex. 43 For complex 1c, the crystal structure was published as an ethanol solvate monomer with a distorted square-planar geometry and ligands in transconfiguration. 44 However, we obtained the crystal structure of 1c without solvent molecules, in which a distorted tetrahedral geometry around zinc was found ( Supplementary Fig. 1 ). The crystals were obtained by liquid diffusion at room temperature using chloroform/hexane solvents. In addition, a new crystal structure for complex 1d was obtained as a monomer with two ligands d coordinated to zinc (Fig. 2, Supplementary Fig. 1 ), forming a tetrahedral geometry similar to that of complex 1f ( Supplementary Fig. 1 ). Crystals for both complexes were obtained by liquid diffusion at room temperature using chloroform/heptane for 1d and chloroform/dichloromethane solvent system for 1f. Crystallographic data for novel crystal structures of 1c, 1d and 1f are given in Supplementary Table 1 . Moreover, complex 1e is known to crystallize in a distorted tetrahedral geometry as a monomer. 45 We have analysed the available crystal structures of zinc-pyrithione complexes as well as the structures obtained by our group (Supplementary Table 2 ). The complexes crystallize either as monomers or as dimers. The geometry in monomeric forms is distorted tetrahedral (τ = 0.70-0.78) and in dimeric forms distorted trigonal bipyramidal (τ = 0.51-0.59) (Supplementary Table 2 ). 

UV-vis spectroscopy was first used to determine if the compounds are stable in aqueous media and therefore suitable for further biological studies (Supplementary Figs. 10-15). The 9 same media were used as for cathepsin L and PL Pro enzymatic assays, i.e. either 1% DMSO/acetate buffer (for the cathepsin L assay) or 1% DMSO/HEPES buffer (for the PL Pro assay). From the UV-vis spectra, it is evident that ligand a and its zinc complex 1a remain stable in acetate buffer (Supplementary Figs. [10] [11] . Ruthenium complex 2a also proved to be a stable compound in this media as well ( Supplementary Fig. 12 ). UV-vis stability measurement of the above-mentioned compounds in HEPES buffer also gave comparable curves . Therefore, the UV-vis stability analysis provided us with encouraging results for further biological assays.

The selected compounds (a, 1a, 2a) were further examined for their stability by 1 

We investigated the inhibitory properties of the synthesized complexes towards two enzymes involved in the development of COVID-19, namely cathepsin L and SARS-CoV-2 PL Pro (Table 1 The introduction of a methyl group at positions 3 (1b), 4 (1c), 5 (1d) and 6 (1e) resulted in somehow stronger inhibition of cathepsin L, compared with the unsubstituted complex 1a (IC50 = 1.88 ± 0.49 µM), with an IC50 of 0.35 ± 0.12 µM for 1b, 0.41 ± 0.08 µM for 1c, 0.44 ± 0.12 µM for 1d, and 0.24 ± 0.05 µM for 1e. Similar values were obtained for the complex with isoquinoline ligand (1f, IC50 = 0.14 ± 0.05 µM) and the complex with methoxysubstituted ligand (1h, IC50 = 0.74 ± 0.13 µM). Interestingly, the zinc complex with quinoline-derived pyrithione 1g showed complex behaviour with cathepsin L that prevented IC50 calculation. In addition, it is important to note that the ligands themselves are much weaker cathepsin L inhibitors compared to their zinc complexes (Supplementary Table 3) .

A reverse trend was observed for PL Pro activity in the case of zinc complex 1b with methylsubstituted pyrithione at position 3, which slightly decreased the inhibitory activity of complex 1b (IC50 = 1.09 ± 0.62 µM) compared to 1a (IC50 = 0.73 ± 0.20 µM). On the other hand, the methyl substituents at the positions 5 and 6 contributes to increased inhibitory strength of complex 1d and 1e (IC50 = 0.22 ± 0.08 µM and 0.26 ± 0.18 µM, respectively), similar to complex 1f with isoquinoline substituent (IC50 = 0.26 ± 0.10 µM) and complex 1h 11 with methoxy substituent (IC50 = 0.14 ± 0.05 µM). However, it is important to note that complex 1f cannot fully inhibit the enzyme. Complex 1c inhibit PL Pro in a similar manner as complex 1a with IC50 value of 0.54 ± 0.25 µM and complex 1g is a slightly weaker inhibitor (IC50 = 1.66 ± 0.31 µM). In addition, it is important to note that the ligands themselves are again much weaker PL Pro inhibitors compared to their zinc complexes (Supplementary Table   3 ). Our study has shown that substitution of parent pyrithione compound with selected groups has some influence on the biological response (enzyme inhibition) but none of the substituted compounds was much more effective. However, we believe that introduction of other groups might bring greater changes and should be tested in the future. 

Following the promising results of the enzymatic assays, we also wanted to test the efficacy of the selected compounds in an ex vivo physiological system of SARS-CoV-2 entry and 12 infection, recently developed and derived from primary human lung tissue (HLT). 46 Although some differences in the inhibition of cathepsin L and PL Pro were observed for zinc complexes 1b-h with various pyrithione derivatives, the differences were not significant compared to 1a. Since the antimicrobial properties of zinc pyrithione 1a have been well studied and this compound is also present in commercial shampoos, we decided to test complex 1a in an ex vivo system for potential antiviral properties. In addition, ligand a was tested as a control and ruthenium complex 2a was tested to investigate the importance of the metal core of the complex in inhibiting viral entry and replication.

The viral entry assay was used to determine how effective the compounds tested (a, 1a, 2a)

were in preventing the entry of pseudoviral particles carrying the SARS-CoV-2 S protein into HLT cells at concentrations of 30 µM, 10 µM, 1 µM, and 0.5 µM (Fig. 4a) . Viral entry was µM for a. Similar to enzyme inhibition assays, ligand a was therefore found to be the worst inhibitor of viral entry, followed by ruthenium complex 2a and zinc complex 1a. Moreover, zinc also contributes to better inhibition of viral entry than ruthenium.

Besides, viral entry inhibition potential of the mixture of zinc acetate and pyrithione a was tested (molar ratio 1 : 2, c(zinc acetate) = 1 µM, 10 µM and 30 µM; Fig. 4b ). In all cases, 13 zinc pyrithione 1a was found to inhibit SARS-CoV-2 entry better than the above combination at all concentrations tested.

In addition to viral entry inhibition, the viability of HLT must also be taken into consideration. As expected, highest cell survival was observed at lowest tested concentration 

During the pandemic, much attention was paid to zinc because of its antiviral properties. Zinc improves mucociliary clearance (removal of viral particles from the lungs) and strengthens the 15 integrity of the respiratory epithelium. Importantly, increased Zn 2+ concentrations may also improve antiviral immunity by upregulating IFNα and prevent inflammation by inhibiting NF-κB signalling. In addition, hypozincemia is associated with loss of smell and taste [10] [11] [12] 17 and is reported to lead to higher severity and mortality of COVID-19 patients. 47 As mentioned in the introduction, Zn 2+ can indirectly inhibit SARS-CoV-2 targets such as ACE2 receptors, furin, RdRp, and M Pro . However, it is important to address the issue of zinc bioavailability. A randomized clinical trial suggests that oral treatment with zinc gluconate alone or in combination with ascorbic acid does not significantly shorten the duration of the COVID-19 symptoms, 48 whereas zinc sulphate tablets may improve survival in COVID-19

patients. However, the results are not clinically applicable due to various limitations of the study. 49 On the other hand, an ongoing clinical trial of intravenous administration of ZnCl2 has so far confirmed its safe use and shown an increase in serum zinc levels. 50, 51 However, oral administration of the drug is much more patient-friendly and is preferred over intravenous use.

Ionophores, molecules that enable the transport of metal ions across a lipid cell membrane, increase zinc uptake and facilitate zinc absorption, thus combating COVID-19. 13,52-54 In a multi-center study testing zinc sulphate and hydroxychloroquine as potential treatments, increased hospital discharge and decreased in-hospital mortality were observed. 55 However, hydroxychloroquine as a therapeutic against COVID-19 should be considered with great caution as it may significantly increase the risk of cardiac arrhythmias. Similarly, a high risk of cardiac dysfunction has been reported for chloroquine. [56] [57] [58] Therefore, the choice of an appropriate chelating agent for zinc is of utmost importance.

Pyrithione a is a known ionophore with the ability to bind zinc ions, increase their intracellular concentration 59 In the present study, we focused on two previously less studied but still very important targets of SARS-CoV-2, namely cathepsin L, which is involved in viral entry, and the protease PL Pro , which is involved in viral replication. Cathepsin L is a cysteine protease that cleaves the spike protein once SARS-CoV-2 is in the endolysosome within the host cell, and as such allows internalization of the virus in a manner other than TMPRSS2 and furin. Cathepsin L has been reported to be overexpressed after infection with SARS-CoV-2, allowing further progression of infection and leading to a vicious cycle: the more cathepsin L is expressed, the more severe the progression of COVID-19. Therefore, cathepsin L is a promising target to prevent SARS-CoV-2 internalization and further replication. 61 In this study, we demonstrated that zinc pyrithione 1a is a promising cathepsin L inhibitor with an IC50 value in the micromolar range (1.88 ± 0.49 µM). Although some differences in cathepsin L inhibitory activity were observed between the tested analogous zinc complexes 1b-h, the methyl/methoxy substituents on pyrithione and its scaffold extension did not have a major influence. On the other hand, the binding of the pyrithione ligands a-h to the zinc core contributes significantly to the inhibition of cathepsin L and PL Pro since the ligands themselves are only weak inhibitors (Supplementary Table 3 The ex vivo system is composed of primary human lung tissue (HLT) and offers many advantages over immortalized cells derived, for instance, from kidney or colon cell lines. The

HLT system provides type II alveolar cells, along with other heterogeneous cell components from lung tissue that are not subjected to any differentiation processes. Importantly, the HLT 18 system also expresses factors that are required for SARS-CoV-2 entry, such as ACE2, Since pyrithione a is known to be a zinc ionophore, the combination of zinc acetate and pyrithione a in molar ratio 1 : 2 was also tested. It was found that the combination of zinc and pyrithione produced weaker inhibition than the zinc pyrithione complexes at comparable concentrations tested. Moreover, when 1 µM zinc acetate and 2 µM pyrithione were applied to the cells, viral entry was not inhibited at all.

In addition, the ex vivo system used also supports the investigation of SARS-CoV-2 replication inhibition. Pyrithione a itself did not inhibit the replication of SARS-CoV-2.

Again, zinc pyrithione 1a was found to be the most active among the compounds tested, providing 81.03% inhibition of SARS-CoV-2 replication at 30 µM, followed by ruthenium complex 2a, which was only able to suppress replication by 36.96%.

The biological activity of the compound is, of course, a prerequisite for its possible use as a therapeutic agent. However, the efficacy of the drug in the body depends on many parameters, including the physicochemical and ADME (absorption, distribution, metabolism, excretion) properties of the drug candidate, which influence the pharmacokinetic and pharmacodynamic properties of the potential drug. The descriptors incorporated into the SwisADME tool showed that zinc pyrithione 1a has promising properties that are favourable for drug design (Supplementary Figure 22) . 63 Generally, the compounds with logP values in the range of 1-4 are considered to be suitable for use as an oral drug. As such predicted logPo/w value of 1.65 for complex 1a meets this requirement. Based on the calculations, 19 complex 1a is expected to have high gastrointestinal absorption without permeation through the blood-brain barrier. Zinc pyrithione 1a also meets the standards of Lipinski's rule of five and thus represents a "drug-like" compound with favourable bioavailability. One parameter that should be considered with a little more caution is the solubility of complex 1a, which should be taken into account when preparing a potential final peroral formulation. 63, 64 Nowadays, however, advances in technological modifications allow many innovative delivery systems to improve oral drug bioavailability, e.g., nanoformulations, liposomes, cocrystallisation, cyclodextrins, polymers etc. 65, 66 In summary, we have shown that zinc pyrithione 1a is a promising candidate to combat COVID-19 and that coordination of two pyrithione (a) ligands specifically to zinc is essential for the desired antiviral activity. Although some modifications should be considered to 

Zinc complexes 1a-h have been prepared according to the following modified procedure. 41 Appropriate ligand a-h (2 mol. equiv.) was dissolved in methanol to which 1M NaOH aqueous solution was added dropwise to obtain pH ~ 8. Ligands b-g were synthesized as previously reported. 36, 38, 67 Newly prepared ligand h was synthesized according to the same procedure as ligands b-e.

Synthesis of ruthenium complex 2a has been reported before by the Turel group. 36

The same buffers as for enzymatic assays were used for UV-vis stability testing ( 

Recombinant procathepsin L was prepared according to the described protocol. 68 Recombinant PL Pro was prepared according to the modified protocol. 69 , where Y represents IFE corrected reaction rate and X represents concentration of a complex. Relative reaction rates for the ligands were determined as ratio of 100 µ over 0 .

Entry viral assay

Triplicates of the dilutions 30, 10, 1, and 0.5 μM of the antiviral compounds a, 1a, and 2a

were tested for their antiviral effect in human lung tissue (HLT) cells using 3 different 23 donors. Pyrithione a was also tested in combination with zinc acetate dihydrate (ZnAc) at different concentrations (2, 20, and 60 μM of pyrithione a), but maintaining a ratio of 2:1. 

The authors declare that the main data supporting the findings of this study are available within the paper and its supplementary information files. Any additional data can be obtained from the corresponding authors MJ.B. and I.T. upon request. 

Characteristics of SARS-CoV-2 and COVID-19

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Structural basis of receptor recognition by SARS-CoV-2

How SARS-CoV-2 makes the cut

Coronavirus biology and replication: implications for SARS-CoV-2

COVID-19 treatments: authorised | European Medicines Agency

COVID-19) | Drugs | FDA

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions

The emerging role of zinc transporters in cellular homeostasis and cancer

Zinc and respiratory tract infections: Perspectives for COVID-19 26 (Review)

Zinc deficiency and taste dysfunction; Contribution of carbonic anhydrase, a zinc-metalloenzyme, to normal taste sensation

Intra-nasal zinc level relationship to COVID-19 anosmia and type 1 interferon response: A proposal

Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities

Antiviral and immunological activity of zinc and possible role in COVID-19

Current evidence supporting the use of orally administered zinc in the treatment of COVID-19

Immunopharmacological perspective on zinc in SARS-CoV-2 infection

The potential impact of zinc supplementation on COVID-19 pathogenesis

A hypothesis for the possible role of zinc in the immunological pathways related to COVID-19 infection

Potential interventions for SARS-CoV-2 infections: Zinc showing promise

An analysis of inhibition of the severe acute respiratory syndrome coronavirus 2 RNAdependent RNA polymerase by zinc ion: an in silico approach

Zinc and SARS-CoV-2: A molecular modeling study of Zn interactions with RNA-dependent RNA-polymerase and 3C-like proteinase enzymes

SARS-CoV-2 M pro inhibition by a zinc ion: structural features and hints for drug design

Zinc 2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro

Zn 2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture

Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery

Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV

Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): Expression, purification, characterization, and inhibition

A novel framework integrating AI model and enzymological experiments 28 promotes identification of SARS-CoV-2 3CL protease inhibitors and activity-based probe

Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in vitro repurposing screen

X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease

The antifungal mechanism of action of zinc pyrithione

Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins

Understanding the mechanism of action of the anti-dandruff agent zinc pyrithione against Malassezia restricta

Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets

Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents

Towards identification of essential structural elements of organoruthenium(II)-pyrithionato complexes for anticancer activity

Organoruthenium complexes with benzo-fused pyrithiones overcome 29 platinum resistance in ovarian cancer cells

Structural isomerism and enhanced lipophilicity of pyrithione ligands of organoruthenium(II) complexes increase inhibition on AChE and BuChE

Structure-activity relationships of pyrithiones-IPC-81 toxicity tests with the antifouling biocide zinc pyrithione and structural analogs

The biological inorganic chemistry of zinc ions

Synthesis and anticancer properties of water-soluble zinc ionophores

Structural characterization of bis(N-oxopyridine-2-thionato)zinc(II)

Synthesis and crystal structure of dinuclear zinc(II) complex with 3-Me-N-oxopyridine-2-thiol

Syntheses and properties of some transition metal complexes with methyl substituted 1-hydroxy-2(1H)-pyridinethione and crystal structure of bis(1-hydroxy-4-methyl-2(1H)pyridinethionato-O,S')zinc(II)

Crystal structures of the cobalt(III), nickel(II), copper(II), and zinc(II) complexes of 2-thio-6-picoline N-oxide

Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

Low zinc levels at admission associates with poor clinical outcomes in SARS-CoV-2 infection

Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: The COVID A to Z randomized clinical trial

Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study

Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol

A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients

A possible application of hinokitiol as a natural zinc ionophore and anti-infective agent for the prevention and treatment of COVID-19 and viral infections

Zinc(II)-the overlooked éminence grise of chloroquine's fight against COVID-19?

Zinc ionophores: chemistry and biological applications

Treatment with zinc is associated with reduced in-hospital mortality among COVID-19 patients: A multi-center cohort study

Hydroxychloroquine with or without azithromycin in mild-tomoderate Covid-19

Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)

QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review

Increase of the intracellular zinc concentration leads to an activation and internalisation of the epidermal growth factor receptor in A549 cells

The antimicrobial and immunomodulatory effects of ionophores for the treatment of human infection

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development

Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

Oral formulations for preclinical studies: Principle, design, and development considerations. in Developing solid oral dosage forms: Pharmaceutical theory and practice

Strategies to improve oral drug bioavailability

Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges

Exploring the influence of the protein environment on metal-binding pharmacophores

A simple and efficient protocol for the production of recombinant cathepsin V and other cysteine cathepsins in soluble form in Escherichia coli

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Rapid determination of enzyme kinetics from 33 fluorescence: Overcoming the inner filter effect

the COVID-19 pandemic), and the grant from the Health Department of the Government of

B is supported by the Miguel Servet program funded by the Spanish Health

performed X-ray analysis and interpreted the data. A.D. and J.Kla. carried out UV-vis and NMR stability experiments. A.D. and M.N. performed cloning, protein expression and purification. A.D performed enzymatic assays. D.P performed viral entry. JG.E performed the replication-competent virus assays. M.G supervised the recollection of the lung tissues, and MJ.B supervised all the ex vivo work. J.Kla. and A.D. contributed to original draft preparation of manuscript

We would like to acknowledge EATRIS Academic Collaboration and their COVID-19 Fast 

The authors declare no competing interests.